MEDICAMENTOUS THERAPY OF THE DUCHENNE MUSCULAR DYSTROPHY AND THE SPINAL MUSCULAR ATROPHY



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the overview the analysis of contemporary scientific researches in the area of medicamentous therapy of the genetical nervomuscular diseases is presented: the overview of spinal muscular atrophy and Duchenne muscular dystrophy has been carried out. Up to the present moment these diseases are incurable, but the common scientific work of geneticists, molecular biologists, clinicians, and pharmacologists gives promising prospects. Many researches are devoted to the question of elimination of the primary pathogenetic cause of these diseases with the usage of methods of the gene therapy.

Full Text

Restricted Access

About the authors

M G Sokolova

North-Western State Medical University named after I.I. Mechnikov

O A Nikishina

North-Western State Medical University named after I.I. Mechnikov

M A Maretina

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

A V Kiselev

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

S V Lobzin

North-Western State Medical University named after I.I. Mechnikov

A A Zuev

North-Western State Medical University named after I.I. Mechnikov

References

  1. Patel K., Macharia R., Amthor H. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a theurapeutic strategy for Duchenne muscular dystrophy // Acta Myologica. 2005. Nо 2. Р. 230-241.
  2. Баранов А.Н., Киселев А.В., Баранов B.C. Генная терапия миодистрофии Дюшенна // Медицинская генетика. 2007. Т. 6, № 4. С. 9-16. [Baranov A.N., Kiselev A.V., Baranov V.S., Russian Journal of Medical Genetics, 2007, vol. 6, No 4, рр. 9-16.]
  3. Janghra N., Morgan J.E., Sewry C.A., Wilson F.X., Davies K.E., Muntoni F., Tinsley J. Correlation of utrophin levels with the dystrophin protein complex and muscle fibreregeneration in Duchenne and Becker Muscular Dystrophy Muscle // PLoS One. 2016. Vol. 11, No 3. Р. 10-17.
  4. Huard J., Mu X., Lu A. Evolving paradigms in clinical pharmacology and therapeutics for the treatment of Duchenne muscular dystrophy // Clin. Pharmacol. Ther. 2016. Vol. 100, No 2. Р. 14-26.
  5. Ramos J., Chamberlain J.S. Gene Therapy for Duchenne muscular dystrophy // Expert. Opin. Orphan Drugs. 2015. Vol. 3, No 11. Р. 1255-1266.
  6. Malik V., Rodino-Klapac L.R., Viollet L., Mendell J.R. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy // Ann Neurol. 2010. Vol. 67, No 6. Р. 71-80.
  7. Bushby K., Finkel R., Wong B., Barohn R., Campbell C., Comi G.P., Connolly A.M., Day J.W., Flanigan K.M., Goemans N., Jones K.J., Mercuri E., Quinlivan R., Renfroe J.B., Russman B., Ryan M.M. Ataluren treatment of patients with nonsense mutation dystrophinopathy // Muscle Nerve. 2014. Vol. 50, No 4. Р. 47-67.
  8. Hofmann Y., Lorson C.L., Stamm S., Androphy E.J., Wirth B. HnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1 // Hum. Mol. Genet. 2002. Vol. 11, No 17. Р. 2037-2049.
  9. Sumner C.J. Molecular mechanisms of spinal muscular atrophy // J. Child Neurol. 2007. Vol. 22. Р. 979.
  10. Zheleznyakova G.Y., Kiselev A.V., Vakharlovsky V.G., Rask-Andersen M., Chavan R., Egorova A.A., Schioth H.B., Baranov V.S. Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III // BMC Medical Genetics. 2011. Vol. 12. Р. 86-96.
  11. Wlodarczyk B.C., Craig J.C., Bennett G. D., Calvin J.A., Finnell R.H. Valproic acid-induced changes in gene expression during Neurulationan mouse model // Teratology. 1996. Vol. 54. Р. 284-297.
  12. Weihl C.C., Connolly A.M., Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy // Neurology. 2006. Vol. 67. Р. 500-501.
  13. Hofmann Y., Lorson C.L., Stamm S., Androphy E.J., Wirth B. Htra2-β stimulates an exonicsplising enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2) // PNAS. 2000. Vol. 97, No 17. Р. 9618-9623.
  14. Brichta L., Hofmann Y., Hahnen E. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy // Human Molecular Genetics. 2003. Vol. 12, No 19. Р. 2481-2489.
  15. Swoboda K.J., Scott C., Reyna S., Prior T.W., LaSalle B., Sorenson S.L., Wood J., Acsadi G., Crawford T.O., Kissel J.T., Krosschell K.J., D'Anjou G., Bromberg M.B., Schroth M.K., Chan G.M., Elsheikh B., Simard L.R. Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy // PLoS. 2009. Vol. 4, No 5. Р. 52-68.
  16. Wirth B., Barkats M., Martinat C., Sendtner M., Gillingwater T.H. Moving towards treatments for spinal muscular atrophy: hopes and limits // Expert Opin. Emerg Drugs. 2015. Vol. 20, No 3. Р. 53-66.
  17. Баранов В.С., Вахарловский В.Г., Команцев В.Н., Глотов О.С., Глотов А.С., Киселев А.В. Первый клинический опыт лечения вальпроевой кислотой больных аутосомно-рецессивной спинальной мышечной атрофией // Медицинская генетика. 2005. Т. 4, № 3. С. 119-122. [Baranov V.S., Vakharlovsky V.G., Komantsev V.N., Glotov O.S., Glotov A.S., Kiselev A.V., Russian Journal of Medical Genetics, 2005, vol. 4, No 3, pp. 119-122.]
  18. Вахарловский В.Г., Команцев В.Н., Любименко В.А., Егоров А.Л., Сезнева Т.Н., Вахарловская М.В., Киселев А.В., Романенко О.П., Баранов В.С. Современные клинико-терапевтические вопросы проксимальной спинальной мышечной атрофии // Нейрохирургия и неврология детского возраста. 2008. № 3. С. 38-48. [Vakharlovsky V.G., Komantsev V.N., Lyubimenko V.A., Egorov A.L., Sezneva T.N., Vakharlovskaya M.V., Kiselev A.V., Romanenko O.P., Baranov V.S., Neurosurgery and Neurology of Children's age, 2008, No 3, pp. 38-48.]
  19. Баранов В.С., Киселев А.В., Вахарловский В.Г., Железнякова Г.Ю., Команцев В.Н., Малышева О.В., Глотов А.С., Иващенко Т.Э., Баранов А.Н. Молекулярно-генетическая природа и опыт фармакотерапии проксимальной спинальной мышечной атрофии // Генетика. 2008. Т. 44, № 10. С. 1325-1337. [Baranov V.S., Kiselev A.V., Vakharlovskiĭ V.G., Zhelezniakova G.Iu., Komantsev V.N., Malysheva O.V., Glotov A.S., Ivashchenko T.E., Baranov A.N., Genetika, 2008, vol. 44, No 10, pp. 1325-1337.]
  20. Swoboda K.J., Scott C., Reyna S. Prior T.W., LaSalle B., Sorenson S.L., Wood J., Acsadi G., Crawford T.O., Kissel J.T., Krosschell K.J., D'Anjou G., Bromberg M.B., Schroth M.K., Chan G.M., Elsheikh B., Simard L.R. Phase II open label study of valproicacid in spinal muscular atrophy // PLoS One. 2009. Vol. 45. Р. 13-27.
  21. Weihl Н., Connolly A.M., Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy // Epub. 2006. Vol. 67. No 3. Р. 115-121.
  22. Swoboda K.J., Scott C.B., Crawford T.O. Simard L.R., Reyna S.P., Krosschell K.J., Acsadi G., Elsheik B., Schroth M.K., D'Anjou G., LaSalle B., Prior T.W., Sorenson S.L., Maczulski J.A., Bromberg M.B., Chan G.M., Kissel J.T. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-Carnitine and Valproicacid in Spinal Muscular Atrophy // PLoS ONE. 2010. Vol. 5. Р. 1-13.
  23. Kissel J.T., Scott C.B., Reyna S.P., Simard L.R., Krosschell K.J., Acsadi G., Elsheik B., Schroth M.K., D'Anjou G., LaSalle B., Prior T.W., Sorenson S., Maczulski J.A., Bromberg M.B., Chan G.M., Swoboda K.J. SMA CARNI-VAL TRIAL PART II: A prospective, single-armed trial of L-Carnitine and Valproic Acid in ambulatory children with Spinal Muscular Atrophy // PLoS ONE. 2011. Vol. 6. Р. 1-11.
  24. Kissel J.T., Elsheikh B., King W.M., Freimer M., Freimer M., Scott C.B., Kolb S.J., Reyna S.P., Crawford T.O., Simard L.R., Krosschell K.J., Acsadi G., Schroth M.K., D'Anjou G., LaSalle B., Prior T.W., Sorenson S., Maczulski J.A., Swoboda K.J. SMA valiant trial: a prospective, double-blind, placebo controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy // Muscle Nerve. 2013. Vol. 4. Р. 1-6.
  25. Riessland M., Brichta L., Hahnen E., Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells // Hum. Genet. 2006. Vol. 120, No 1. Р. 10-21.
  26. Liu H., Yazdani A., Murray L.M., Beauvais A., Kothary R. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy // PLoS One. 2014. Vol. 9, No 7. Р. 63-71.
  27. Liang W., Yuo C., Chang J., Chen Y.C., Chang Y.F., Wang H.Y., Ju Y.H., Chiou S.S., Jong Y.J. The effect of hydroxyurea in spinal muscular atrophy cells and patients // J. Neurol. Sci. 2008. Vol. 268. Р. 87-94.
  28. Tiziano F.D., Lomastro R., Pinto A.M., Messina S., D'Amico A., Fiori S., Angelozzi C., Pane M., Mercuri E., Bertini E., Neri G., Brahe C. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design // J. Med Genet. 2010. Vol. 47, No 12. Р. 56-68.
  29. Hua Y., Sahashi K., Hung G., Rigo F., Passini M.A., Bennett C.F., Krainer A.R. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model // Genes and Development. 2010. Vol. 24. Р. 1634-1644.
  30. Passini M.A., Bu J., Richards A.M., Kinnecom C., Sardi S.P., Stanek L.M., Hua Y., Rigo F., Matson J., Hung G., Kaye E.M., Shihabuddin L.S., Krainer A.R., Bennett C.F., Cheng S.H. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe Spinal Muscular Atrophy // Science Translational Medicine. 2011. Vol. 3, No 72. Р. 1-11.
  31. Swoboda K., Chiriboga C., Darras B., Iannaccone S., Montes J., De Vivo D.C., Norris D.A., Bennett C.F., Bishop K.M. First-in-human phase I study to assess safety, tolerability and dose for intrathecal injection of ISIS-SMNRx in SMA patients // Neuromuscular Disorders. 2013. Vol. 23. Р. 797-798.
  32. Finkel R.S., Day J., Chiriboga C., Vasjar J., Cook D., De Vivo D.C., Yamashita M., Rigo F., Hung G., Schneider E., Norris D.A., Xia S., Bennett C.F., Bishop K.M. Results of a phase 2 open-label study of ISIS-SMNRx in patients with infantile (Type 1) spinal muscular atrophy // Neuromuscular Disorders. 2014. Vol. 24. Р. 910-920.
  33. Haché M., Swoboda K. J., Sethna N., Farrow-Gillespie A., Khandji A., Xia S., Bishop K.M. Intrathecalinjections in children with Spinal Muscular Atrophy: Nusinersenclinical trial experience // Journal of Child Neurology. 2016. Vol. 27. Р. 1-8.
  34. Naryshkin N., Weetall M., Dakka A., Narasimhan J., Zhao X., Feng Z., Ling K.K., Karp G.M., Qi H., Woll M.G., Chen G., Zhang N., Gabbeta V., Vazirani P., Bhattacharyya A., Furia B., Risher N., Sheedy J., Kong R., Ma J., Turpoff A., Lee C.S., Zhang X., Moon Y.C., Trifillis P., Welch E.M., Colacino J.M., Babiak J., Almstead N.G., Peltz S.W., Eng L.A., Chen K.S., Mull J.L., Lynes M.S., Rubin L.L., Fontoura P., Santarelli L., Haehnke D., McCarthy K.D., Schmucki R., Ebeling M., Sivaramakrishnan M., Ko C.P., Paushkin S.V., Ratni H., Gerlach I., Ghosh A., Metzger F. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy // Science. 2014. Vol. 345. Р. 688-693.
  35. Palacino J., Swalley S.E., Song C., Cheung A.K., Shu L., Zhang X., Van Hoosear M., Shin Y., Chin D.N., Keller C.G., Beibel M., Renaud N.A., Smith T.M., Salcius M., Shi X., Hild M., Servais R., Jain M., Deng L., Bullock C., McLellan M., Schuierer S., Murphy L., Blommers M.J., Blaustein C., Berenshteyn F., Lacoste A., Thomas J.R., Roma G., Michaud G.A., Tseng B.S., Porter J.A., Myer V.E., Tallarico J.A., Hamann L.G., Curtis D., Fishman M.C., Dietrich W.F., Dales N.A., Sivasankaran R. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice // Nature Chemical Biology. 2015. Vol. 4. Р. 1-7.
  36. Bordet T., Berna P., Abitbol J.L., Pruss R.M. Оlesoxime (TRO19622): A Novel mitochondrial-targeted neuroprotectivecompound // Pharmaceuticals (Basel). 2010. Vol. 3, No 2. Р. 345-368.
  37. Соколова М.Г., Лобзин С.В., Литвиненко И.В., Резванцев М.В. Изучение активности белков, регулирующих апоптоз у детей с наследственными и приобретенными заболеваниями нервной системы // Профилактическая и клиническая медицина. 2016. № 4 (3). С. 18-26. [Sokolova M.G., Lobzin S.V., Litvinenko I.V., Rezvantsev M.V., Preventive and cilinical medicine, 2016, No 4 (61), pp. 53-58.]
  38. Butchbach M.E.R., Singh J., Þorsteinsdóttir M., Saieva L., Slominski E., Thurmond J., Andrésson T., Zhang J., Edwards J.D., Simard L.R., Pellizzoni L., Jarecki J., Burghes A.H., Gurney M.E. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy // Human Molecular Genetics. 2010. Vol. 19, N. 3. Р. 454-467.
  39. Gogliotti R.G., Cardona H., Singh J., Bail S., Emery C., Kuntz N., Jorgensen M., Durens M., Xia B., Barlow C., Heier C.R., Plasterer H.L., Jacques V., Kiledjian M., Jarecki J., Rusche J., Di Donato C.J. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models // Human Molecular Genetics. 2013. Vol. 20. Р. 1-18.
  40. Van Meerbeke J.P., Gibbs R.M., Plasterer, H.L., Miao W., Feng Z., Lin M.-Y., Rucki A.A., Wee C.D., Xia B., Sharma S., Jacques V., Li D.K., Pellizzoni L., Rusche J.R., Ko C.-P., Sumner C.J. The therapeutic effects of RG3039 in severe Spinal Muscular Atrophy mice and normal human volunteers // Neurology. 2012. Vol. 78, N. 1. Р. 1-18.
  41. Oliván S., Calvo A.C., Rando A., Herrando-Grabulosa M., Manzano R., Zaragoza P., Tizzano E.F., Aquilera J., Osta R. Neuroprotective effect of non-viral gene therapy treatment based on tetanus toxin C-fragment in a severe mouse model of Spinal Muscular Atrophy // Front. Mol. Neurosci. 2016. Vol. 24, No 9. Р. 38-49.
  42. Отчет о V международном конгрессе по миологии во Франции 2016 г. // Нервно-мышечные болезни. 2016. Т. 6, № 2. С. 58-60. [Report of the V international Congress of myology in France, Neuromuscular Diseases, 2016, vol. 6, No 2, pp. 58-60.]
  43. Tiwari S.K., Chaturvedi R.K. Peptide Therapeutics in Neurodegenerative Disorders // Curr. Med. Chem. 2014. No 1. Р. 2-17.
  44. Teng K.K., Hempstead B.L. Neurotrophins and their receptors: Signaling trios in complex biological systems // Cell Mol. Life Sci. 2004. Vol. 61. Р. 35-48.
  45. Соколова М.Г., Лобзин С.В., Резванцев М.В. Особенности нейротрофической регуляции у больных СМА 2 типа // Нейрохирургия и неврология детского возраста. 2015. № 3 (45). С. 8-15. [Sokolova M.G., Lobzin S.V., Rezvantsev M.V., Pediatric neurosurgery and neurology, 2015, No 3 (45), pp. 12-19.]
  46. Sokolova M.G., Lobzin S.V., Litvinenko I.V., Penniyaynen V.A., Rezvantsev M.V. Search for new approaches to treating patients with spinal muscular atrophy, 2 type as part of clinical-experimental study // Archiv euromedica. 2016. Vol. 6, Nо 2. pp. 41-45.
  47. Нерешенные проблемы неврологии и психиатрии: монография / под ред. В.П. Волкова. Новосибирск: СибАК, 2016. 114 с. [Unsolved problems of neurology and psychiatry: monograph, under the ed. of V. P. Volkov, Novosibirsk: Sibak, 2016, р. 114.]
  48. Соколова М.Г., Пеннияйнен В.А. Обоснование лечения спинальной мышечной атрофии 2-го типа с позиции изучения патогенетических молекулярно-клеточных механизмов в органотипической культуре ткани (клинико-экспериментальное исследование) // Нервно-мышечные болезни. 2016. Т. 6. С. 59-60. [Sokolova M.G., Penniyaynen V.A., Neuromuscular Diseases, 2016, vol. 6, No 3, pp. 59-60]
  49. Соколова М.Г., Лобзин С.В., Пеннияйнен В.А., Кипенко А.В., Лопатина Е.В., Резванцев М.В. Моделирование биохимических условий внутриорганной среды при спинальной мышечной атрофии 2 типа в органотипической культуре ткани // Вестник МГОУ. Серия: Естественные науки. 2016. № 4. С. 47-57. [Sokolova M., Lobzin S., Penniyaynen V., Kipenko A., Lopatina E., Rezvantsev M., Bulletin of the Moscow state regional university. Series Natural Sciences. 2016. No 4. pp. 47-57.]
  50. Sokolova М., Penniyaynen V., Kipenko A., Aleksandrov N., Dobrota D., Lopatina E. Study of reinnervation process in patients with 2 type of spinal muscular atrophy: clinical experimental study // Activitas Nervosa Superior Rediviva. 2015. Vol. 5, No 4. pp. 101-104.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Sokolova M.G., Nikishina O.A., Maretina M.A., Kiselev A.V., Lobzin S.V., Zuev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies